Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02914327
Title Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Esanex Inc.
Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST